Abstract
Osteosarcoma (OS) is the second most common primary malign bone neoplasm after multiple myeloma. Despite systemic chemotherapy, OS may give rise to local recurrences and metastases. Resistance to chemotherapy is not rare and is likely to occur in a high number of patients. Novel therapeutic approaches are required in order to efficiently treat osteosarcoma. Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) and proteasome inhibitors (epoxomicin, MG132, bortezomib) represent new promising approaches in cancer treatment. The aim of our study is to elucidate the effects of epoxomicin alone or in combination with TRAIL in two TRAIL-resistant OS cell lines, Saos-2 and MG-63 namely. We determined the cytotoxic effects of epoxomicin and/or TRAIL on these two types of OS cells using dimethylthiazolyl 2,5 diphenyltetrazolium bromide (MTT) test and measured apoptosis markers such as pro-apoptotic Bax levels and caspase-3, -8, -9 activities. We used TUNEL assay to demonstrate apoptosis. We investigated dose and time dependent survival rates of OS cells and determined LD50 doses of epoxomicin and TRAIL on OS cell viability after 24, 48, and 72 hour incubations. Concurrent incubation with TRAIL and epoxomicin for 24 hour significantly increased caspase-3, caspase-8, caspase-9 activities and Bax protein levels. Our study demonstrated that the combination of TRAIL with epoxomicin enhances apoptosis, and overcomes TRAIL resistance, denoting promising results for OS therapy in the future.
Keywords: Apoptosis, Epoxomicin, MG-63, Osteosarcoma, Saos-2, TRAIL, TRAIL-resistance.
Anti-Cancer Agents in Medicinal Chemistry
Title:Epoxomicin Sensitizes Resistant Osteosarcoma Cells to TRAIL Induced Apoptosis
Volume: 15 Issue: 4
Author(s): Ferhat Hanikoglu, Aysegul Cort, Hakan Ozben, Aysegul Hanikoglu and Tomris Ozben
Affiliation:
Keywords: Apoptosis, Epoxomicin, MG-63, Osteosarcoma, Saos-2, TRAIL, TRAIL-resistance.
Abstract: Osteosarcoma (OS) is the second most common primary malign bone neoplasm after multiple myeloma. Despite systemic chemotherapy, OS may give rise to local recurrences and metastases. Resistance to chemotherapy is not rare and is likely to occur in a high number of patients. Novel therapeutic approaches are required in order to efficiently treat osteosarcoma. Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) and proteasome inhibitors (epoxomicin, MG132, bortezomib) represent new promising approaches in cancer treatment. The aim of our study is to elucidate the effects of epoxomicin alone or in combination with TRAIL in two TRAIL-resistant OS cell lines, Saos-2 and MG-63 namely. We determined the cytotoxic effects of epoxomicin and/or TRAIL on these two types of OS cells using dimethylthiazolyl 2,5 diphenyltetrazolium bromide (MTT) test and measured apoptosis markers such as pro-apoptotic Bax levels and caspase-3, -8, -9 activities. We used TUNEL assay to demonstrate apoptosis. We investigated dose and time dependent survival rates of OS cells and determined LD50 doses of epoxomicin and TRAIL on OS cell viability after 24, 48, and 72 hour incubations. Concurrent incubation with TRAIL and epoxomicin for 24 hour significantly increased caspase-3, caspase-8, caspase-9 activities and Bax protein levels. Our study demonstrated that the combination of TRAIL with epoxomicin enhances apoptosis, and overcomes TRAIL resistance, denoting promising results for OS therapy in the future.
Export Options
About this article
Cite this article as:
Hanikoglu Ferhat, Cort Aysegul, Ozben Hakan, Hanikoglu Aysegul and Ozben Tomris, Epoxomicin Sensitizes Resistant Osteosarcoma Cells to TRAIL Induced Apoptosis, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (4) . https://dx.doi.org/10.2174/1871520615666150209111650
| DOI https://dx.doi.org/10.2174/1871520615666150209111650 |
Print ISSN 1871-5206 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Photosensitive Drugs, Herbal Medicine, and Nanotherapeutics for Targeted Cancer Therapy
This thematic issue focuses on cutting-edge research in photosensitive drugs, herbal medicine, and nanotechnology-based cancer therapies. It explores emerging trends in bibliometric analysis of photosensitizers, the role of herbal compounds in cancer networks, theranostic nanoprodrugs, phthalocyanine-based photodynamic therapy, nano-platforms for cancer treatment, and the design, synthesis, and PK-PD evaluation of ...read more
Nature Inspired Heterocyclic Scaffolds as Targeted Potential Anticancer Agents
Cancer remains one of the leading causes of mortality worldwide, posing major challenges due to tumor complexity, multidrug resistance, and treatment toxicity. The convergence of natural product chemistry, nanotechnology, and molecular medicine has transformed anticancer drug discovery. Natural bioactive compounds and engineered heterocycles have inspired the design of nutraceuticals, nanoformulations, ...read more
Plant-Derived Bioactive Compounds: From Extraction to Target Identification, Chemical Modification, Nanoencapsulation, and Anti-Proliferative Activity Assessment
The role of plants is not limited solely to the presence of nutrients necessary for the growth and maintenance of the organism, since several components and metabolites are endowed with multiple biological activities, which give an important biological role to these natural matrices. In particular, the intake of plant-rich in ...read more
Synergistic Strategies to Tumor Immune Modulation and Chemotherapeutic Interventions
Chemotherapeutic agents possess the dual capability of directly killing tumor cells while simultaneously enhancing antitumor responses through immune modulation. Recent advances have highlighted the synergistic interactions between chemical therapies and immunotherapeutic strategies, particularly through mechanisms such as chemotherapy-induced immunogenic cell death (ICD) and the influence of small-molecule drugs on the ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Modulating microRNAs in Atherosclerotic Vascular Disease
Current Vascular Pharmacology Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology Efficacy of Pegylated Lyposomal Anthracyclines and of Intra-Arterial Carboplatin and Doxorubicin Combined with Local Hyperthermia in a Case of Malignant Endovascular Papillary Angioendothelioma
Current Drug Delivery Identification of HIV Inhibitors Guided by Free Energy Perturbation Calculations
Current Pharmaceutical Design Pharmacological and Biological Therapies for Metabolic Bone Disease in Critical Illness: An Integrative Physiology Approach
Current Drug Therapy Effect-based Hazard Identification of House Dust by In Vitro Assays Detecting Dioxin-like Compounds, Thyroid and Reproductive Toxicants
Current Organic Chemistry Recent Advances in Enone and NO-Releasing Derivatives of Oleanolic Acid with Anti-cancer Activity
Mini-Reviews in Organic Chemistry Ceramide: Therapeutic Potential in Combination Therapy for Cancer Treatment
Current Drug Metabolism Recent Design and Structure-Activity Relationship Studies on the Modifications of DHFR Inhibitors as Anticancer Agents
Current Medicinal Chemistry Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design <i>Punica granatum</i> Peel Waste - An Underutilized Substrate of Therapeutic Potential: An Overview
Recent Advances in Food, Nutrition & Agriculture The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry 2-Methoxyestradiol as a Potential Cytostatic Drug in Gliomas?
Anti-Cancer Agents in Medicinal Chemistry Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy
Current Cancer Drug Targets The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry Atomic Layers in Electrochemical Biosensing Applications - Graphene and Beyond
Current Organic Chemistry





